Abbott and the American Diabetes Association? Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
November 09, 2021 at 09:00 am EST
Share
Abbott and the American Diabetes Association? announced the launch of their first joint community health partnership. The community initiative, which is the first program under the ADA'sHealth Equity Now? platform, will launch in Columbus, Ohio, and be conducted in partnership with the National Center for Urban Solutions (NCUS), a Columbus-based organization focused on providing solutions in workforce development, education and wellness. The program seeks to better understand and address healthcare disparities for people of color living with diabetes, while fostering accessibility of diabetes care technology within the community. As part of the program, NCUS will provide up to 150 Black adults living with diabetes in the Columbus community with health education and access to Abbott's FreeStyle? Libre flash glucose monitoring technology. By removing existing barriers to tools and technology, this program aims to demonstrate how continuous glucose monitoring can help improve diabetes management and quality of life for Black people living with diabetes in the Columbus community. Black Americans are 60% more likely to be diagnosed with diabetes and much less likely to have their condition well managed largely because care can be cost prohibitive. Further, Black Americans are at the most pronounced disadvantage when it comes to access to continuous glucose monitoring. This is one of the reasons why this project was established ? to create awareness of healthcare disparities and find holistic solutions to drive improved health outcomes. ADA's Health Equity Now platform aims to ensure that the more than 122 million Americans living with diabetes and prediabetes, along with millions more at risk for diabetes, have equal access to health resources in cost, care, cure, community and cuisine that can create a future without unjust health disparities. Abbott's FreeStyle Libre technology was built with access and affordability in mind to make it broadly available to all people with diabetes. This aligns to Abbott's2030 Sustainability Plan, which has a clear focus on innovating for access and affordability with the goal of improving the lives of one in every three people on the planet every year by 2030.
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
- diagnostic systems and instruments (39.1%);
- vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (15.9%).
Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Abbott and the American Diabetes Association? Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
ABBOTT LABORATORIES 
